Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2016-09-12 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
七届十五次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed by the Supervisory Board of Harbin Pharmaceutical Group Co., Ltd. It details the approval of adjustments to a restricted stock incentive plan and the verification of the incentive recipients. The document includes voting results and mentions compliance with relevant laws and regulations. It is not a full report but an official announcement of board decisions related to management incentives. This fits best under Board/Management Information (MANG) as it concerns internal governance decisions and supervisory board resolutions.
2016-09-12 Chinese
独立董事关于公司限制性股票激励计划（草案修订稿）及摘要的独立意见
Remuneration Information Classification · 95% confidence The document is an independent opinion from the independent directors of 哈药集团股份有限公司 regarding the company's restricted stock incentive plan (draft revision). It discusses compliance with relevant laws and regulations, qualifications of incentive recipients, and the benefits of the incentive plan. The document is a formal opinion letter rather than a full report or announcement of voting results. It does not contain financial statements or detailed financial data, nor is it a certification or a brief announcement. It is related to governance and management decisions about stock incentives, which aligns best with Remuneration Information filings that detail compensation and incentive plans for executives and directors.
2016-09-12 Chinese
七届十五次监事会决议
Board/Management Information Classification · 95% confidence The document is a resolution from the supervisory board (监事会) of 哈药集团股份有限公司 regarding the approval and verification of a restricted stock incentive plan. It is a formal meeting decision document, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. It is also not an announcement of voting results at a shareholder meeting, but rather a board-level resolution. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2016-09-12 Chinese
限制性股票激励计划（草案修订稿）
Board/Management Information Classification · 95% confidence The document is a detailed plan titled "哈药集团股份有限公司 限制性股票激励计划（草案修订稿）" which translates to Harbin Pharmaceutical Group Co., Ltd. Restricted Stock Incentive Plan (Draft Revision). It extensively discusses the company's stock incentive plan, including the number of shares to be granted, eligibility criteria, performance conditions, lock-up periods, accounting treatment, and procedures for granting and unlocking restricted stock. The document references relevant laws and regulations governing stock incentive plans, such as the Company Law of the People's Republic of China, Securities Law, and specific regulatory notices related to state-owned enterprises and stock incentive management. It also includes detailed tables on stock allocation, performance targets, and cost amortization schedules. The document is not a financial report, earnings release, or regulatory announcement but a comprehensive management plan related to stock-based compensation and incentives for directors, senior management, and key employees. This type of document fits best under the category of Board/Management Information (MANG), as it relates to management decisions and governance regarding stock incentives for company executives and employees. The document length (15,000 characters) and content confirm it is the plan itself, not merely an announcement or summary, so it is not classified as RPA or RNS.
2016-09-12 Chinese
限制性股票激励计划实施考核管理办法（修订稿）
Governance Information Classification · 95% confidence The document is titled as a management method for the implementation and assessment of a restricted stock incentive plan for 哈药集团股份有限公司. It details the purpose, principles, scope, assessment institutions, performance evaluation indicators, assessment periods, procedures, and feedback related to the stock incentive plan. The content focuses on governance and management of the stock incentive plan rather than financial results, audit, or regulatory announcements. It is a governance-related document outlining internal rules and procedures for performance assessment tied to stock incentives. It does not contain financial statements or earnings data, nor is it an announcement or a report publication notice. Therefore, the document best fits the category of Governance Information (CGR). The document length is 2318 characters, which is relatively short but contains substantive governance content, not just an announcement or certification.
2016-09-12 Chinese
七届十七次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It details decisions made at the 17th meeting of the 7th board of directors, including approval of a restricted stock incentive plan draft and adjustments to the incentive plan's target list. It also mentions the need for further approvals and submission to the shareholders' meeting. The document is an announcement of board decisions rather than a full management report or financial statement. It fits the category of Board/Management Information (MANG) as it relates to board resolutions and governance decisions.
2016-09-12 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.